A brief episode of anger triggered by a past experience has the potential to increase stroke risk by weakening the ability of blood vessels to relax, according to a study published in the Journal of the American Heart Association.
Advertisement
The National Kidney Foundation will honor distinguished health care professionals at the 2024 Spring Clinical Meetings.
Phase III data from the CLIMB SCD-121 trial verified the efficacy of exa-cel in eliminating vaso-occlusive crises in SCD.
Age, weight, graft failure, and donor type are some predictors of pain crisis after HSCT in patients with SCD.
Researchers studied the effect of intensive blood pressure control on the progression of IgAN.
Dr. Marisa Bittoni discusses the possible link between vaping and lung cancer risk.
Drs. Nataliya Uboha and Christopher Lieu highlight a recent analysis of the KRYSTAL-1 trial for metastatic colorectal cancer.
Researchers explored the association between CSVD and CKD plus the potential role of hypertension in this association.
The TransMet trial was developed to determine the efficacy of chemotherapy with LT compared with chemotherapy alone.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Drs. Nataliya Uboha and Christopher Lieu highlight a recent analysis of the KRYSTAL-1 trial for metastatic colorectal cancer.
The TransMet trial was developed to determine the efficacy of chemotherapy with LT compared with chemotherapy alone.
ASCO has issued a companion piece to previously released guidelines addressing commonly asked questions.
HERCESSI was developed by Accord BioPharma, Inc., the US specialty division of Intas Pharmaceuticals Ltd.
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
The study’s primary end point was objective response rate determined through blinded independent central review.
The Latest From Heme Today
Phase III data from the CLIMB SCD-121 trial verified the efficacy of exa-cel in eliminating vaso-occlusive crises in SCD.
Age, weight, graft failure, and donor type are some predictors of pain crisis after HSCT in patients with SCD.
The US FDA has approved fidanacogene elaparvovec-dzkt, a gene therapy for adults with hemophilia B.
Oral and intravenous iron supplementation effectively treated restless legs syndrome in patients with iron deficiency anemia.
In the one-year, fixed-dose extension period of the ESTIMATE study, mitapivat showed continued safety and efficacy in SCD.
Etavopivat was safe and increased hemoglobin, decreased hemolysis, and improved red blood cells in patients with SCD.
